HRP20191771T1 - Anti-adrenomedulin (adm) antitijelo ili fragment anti-adm antitijela ili anti-adm non-ig skela za uporabu u terapiji akutne bolesti ili akutnog stanja pacijenta za stabiliziranje cirkulacije - Google Patents
Anti-adrenomedulin (adm) antitijelo ili fragment anti-adm antitijela ili anti-adm non-ig skela za uporabu u terapiji akutne bolesti ili akutnog stanja pacijenta za stabiliziranje cirkulacije Download PDFInfo
- Publication number
- HRP20191771T1 HRP20191771T1 HRP20191771TT HRP20191771T HRP20191771T1 HR P20191771 T1 HRP20191771 T1 HR P20191771T1 HR P20191771T T HRP20191771T T HR P20191771TT HR P20191771 T HRP20191771 T HR P20191771T HR P20191771 T1 HRP20191771 T1 HR P20191771T1
- Authority
- HR
- Croatia
- Prior art keywords
- adm
- antibody
- adrenomedullin
- binds
- scaffold
- Prior art date
Links
- 102000008394 Immunoglobulin Fragments Human genes 0.000 title claims 25
- 108010021625 Immunoglobulin Fragments Proteins 0.000 title claims 25
- 230000001154 acute effect Effects 0.000 title claims 24
- 208000030090 Acute Disease Diseases 0.000 title claims 21
- 238000002560 therapeutic procedure Methods 0.000 title claims 21
- 230000000087 stabilizing effect Effects 0.000 title claims 2
- 102000004379 Adrenomedullin Human genes 0.000 claims 39
- 101800004616 Adrenomedullin Proteins 0.000 claims 39
- ULCUCJFASIJEOE-NPECTJMMSA-N adrenomedullin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H]1C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)[C@@H](C)O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 ULCUCJFASIJEOE-NPECTJMMSA-N 0.000 claims 39
- 101000690940 Homo sapiens Pro-adrenomedullin Proteins 0.000 claims 13
- 239000012634 fragment Substances 0.000 claims 12
- 102100026651 Pro-adrenomedullin Human genes 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 230000001839 systemic circulation Effects 0.000 claims 5
- 230000004872 arterial blood pressure Effects 0.000 claims 3
- 230000003472 neutralizing effect Effects 0.000 claims 3
- 230000006641 stabilisation Effects 0.000 claims 3
- 238000011105 stabilization Methods 0.000 claims 3
- 102100021243 G-protein coupled receptor 182 Human genes 0.000 claims 2
- 108010063640 adrenomedullin receptors Proteins 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 150000003943 catecholamines Chemical class 0.000 claims 2
- 238000010230 functional analysis Methods 0.000 claims 2
- 102000046663 human ADM Human genes 0.000 claims 2
- 230000014759 maintenance of location Effects 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102000016550 Complement Factor H Human genes 0.000 claims 1
- 108010053085 Complement Factor H Proteins 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 229940124572 antihypotensive agent Drugs 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000004768 organ dysfunction Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000008085 renal dysfunction Effects 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- 239000005526 vasoconstrictor agent Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7095—Inflammation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Microbiology (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
Claims (20)
1. Anti-Adrenomedulin (ADM) antitijelo ili fragment anti-ADM antitijela koji se veže na adrenomedulin ili anti-ADM non-Ig skela koja se veže na adrenomedulin
a) za uporabu u terapiji akutne bolesti ili akutnog stanja pacijenta za stabiliziranje sustavne cirkulacije spomenutog pacijenta pri čemu spomenuti pacijent ima potrebu za stabiliziranjem sustavne cirkulacije i prikazuje otkucaje srca od > 100 otkucaja /min i/ili < 65 mm Hg srednji arterijski tlak te pri čemu stabiliziranje sustavne cirkulacije znači povećanje srednjeg arterijskog tlaka preko 65 mmHg ili
b) za uporabu u prevenciji povećanja otkucaja srca na > 100 otkucaja/min i/ili smanjenja srednjeg arterijskog tlaka na < 65 mm Hg kod pacijenata koji imaju akutnu bolest ili akutno stanje
te pri čemu se spomenuto antitijelo ili fragment antitijela ili non-Ig skela veže na regiju s barem 4 amino kiseline unutar sekvence od aa 1-21 zrelog humanog ADM: YRQSMNNFQGLRSFGCRFGTC (SEQ ID NO: 23).
2. Anti-Adrenomedulin antitijelo ili fragment anti-ADM antitijela koji se veže na adrenomedulin ili anti-ADM non-Ig skela koja se veže na adrenomedulin za uporabu u terapiji akutne bolesti ili akutnog stanja pacijenta prema zahtjevu 1, pri čemu spomenuto antitijelo ili fragment ili skela smanjuje vazopresorsku potrebu, npr. potrebu katekolamina, spomenutog pacijenta.
3. Anti-Adrenomedulin antitijelo ili fragment anti-ADM antitijela koji se veže na adrenomedulin ili anti-ADM non-Ig skela koja se veže na adrenomedulin za uporabu u terapiji akutne bolesti ili akutnog stanja pacijenta prema zahtjevu 1 ili 2, pri čemu je spomenuto antitijelo ili fragment antitijela ili non-Ig skela ne-neutralizirajuće anti-ADM antitijelo ili ne-neutralizirajući fragment anti-adrenomedulin antitijela ili ne-neutralizirajuća anti-ADM non-Ig skela.
4. Anti-Adrenomedulin antitijelo ili fragment anti-ADM antitijela koji se veže na adrenomedulin ili anti-ADM non-Ig skela koja se veže na adrenomedulin za uporabu u terapiji akutne bolesti ili akutnog stanja pacijenta prema bilo kojem od zahtjeva 1 do 3, pri čemu je spomenuto antitijelo ili fragment antitijela ili non-Ig skela monospecifično.
5. Anti-Adrenomedulin antitijelo ili fragment anti-ADM antitijela koji se veže na adrenomedulin ili anti-ADM non-Ig skela koja se veže na adrenomedulin za uporabu u terapiji akutne bolesti ili akutnog stanja pacijenta prema bilo kojem od zahtjeva 1 do 4, pri čemu spomenuto antitijelo ili fragment ili skela pokazuje afinitet vezanja na ADM od barem 10-7 M pri čemu se spomenuti afinitet vezanja određuje prema Primjeru 1.
6. Anti-Adrenomedulin antitijelo ili fragment anti-ADM antitijela koji se veže na adrenomedulin ili anti-ADM non-Ig skela koja se veže na adrenomedulin za uporabu u terapiji akutne bolesti ili akutnog stanja pacijenta prema bilo kojem od zahtjeva 1 do 5, pri čemu spomenuto antitijelo ili fragment ili skela nije ADM-vezujući-Protein-1, faktor komplementa H.
7. Anti-Adrenomedulin antitijelo ili fragment anti-ADM antitijela koji se veže na adrenomedulin ili anti-ADM non-Ig skela koja se veže na adrenomedulin za uporabu u terapiji akutne bolesti ili akutnog stanja pacijenta prema bilo kojem od zahtjeva 1 do 6, pri čemu spomenuto antitijelo ili fragment ili skela prepoznaje i veže se na epitop koji sadrži N-terminalni kraj amino kiseline 1 zrelog humanog ADM i pri čemu spomenuto antitijelo ili fragment ili skela ne bi vezalo niti adrenomedulin proširenog N-terminala niti adrenomedulin modificiranog N-terminala niti adrenomedulin degradiranog N-terminala.
8. Anti-Adrenomedulin antitijelo ili fragment anti-ADM antitijela koji se veže na adrenomedulin ili anti-ADM non-Ig skela koja se veže na adrenomedulin za uporabu u terapiji akutne bolesti ili akutnog stanja pacijenta prema bilo kojem od zahtjeva 1 do 7, pri čemu spomenuto antitijelo ili fragment ili skela je ADM stabilizirajuće antitijelo ili fragment ili skela koje povećava polu-život, t1/2 polu retencijsko vrijeme, adrenomedulina u serumu, krvi, plazmi barem 10 %, ili barem 50 % ili > 50 % ili > 100 %.
9. Anti-Adrenomedulin antitijelo ili fragment anti-ADM antitijela koji se veže na adrenomedulin ili anti-ADM non-Ig skela koja se veže na adrenomedulin za uporabu u terapiji akutne bolesti ili akutnog stanja pacijenta prema bilo kojem od zahtjeva 1 do 8, pri čemu spomenuto antitijelo ili fragment ili skela blokira cirkulirajuću ADM bioaktivnost ne više od 80 %, poželjno ne više od 50 % kada se bioaktivnost ADM u humanom rekombinantnom Adrenomedulin receptoru cAMP određuje funkcionalnom analizom prema Primjeru 2.
10. Anti-Adrenomedulin antitijelo ili fragment anti-ADM antitijela koji se veže na adrenomedulin ili anti-ADM non-Ig skela koja se veže na adrenomedulin za uporabu u terapiji akutne bolesti ili akutnog stanja pacijenta prema bilo kojem od zahtjeva 1 do 9, pri čemu spomenuto antitijelo ili fragment ili skela je modulirajuće anti-ADM antitijelo ili modulirajući anti-adrenomedulin fragment antitijela ili modulirajuća anti-ADM non-Ig skela koja povećava polu-život, t1/2 polu retencijsko vrijeme, adrenomedulina u serumu, krvi, plazmi barem 10 %, ili barem 50 % ili > 50 % ili > 100 % i koja blokira bioaktivnost ADM na ne više od 80 %, poželjno ne više od 50 % kada se bioaktivnost ADM u humanom rekombinantnom Adrenomedulin receptoru cAMP određuje funkcionalnom analizom prema Primjeru 2.
11. Anti-Adrenomedulin antitijelo ili fragment anti-ADM antitijela koji se veže na adrenomedulin za uporabu u terapiji akutne bolesti ili akutnog stanja pacijenta prema bilo kojem od zahtjeva 1 do 10, pri čemu spomenuto antitijelo ili fragment je humano monoklonsko antitijelo ili fragment koji se veže na ADM pri čemu teški lanac sadrži sekvence
SEQ ID NO: 1
GYTFSRYW
SEQ ID NO: 2
ILPGSGST
SEQ ID NO: 3
TEGYEYDGFDY
i pri čemu laki lanac sadrži sekvence
SEQ ID NO:4
QSIVYSNGNTY
SEQ ID NO: 5
RVS
SEQ ID NO: 6
FQGSHIPYT.
12. Anti-Adrenomedulin antitijelo ili fragment anti-ADM antitijela koji se veže na adrenomedulin za uporabu u terapiji akutne bolesti ili akutnog stanja pacijenta prema zahtjevu 11, pri čemu spomenuto antitijelo ili fragment sadrži sekvencu odabranu iz skupine koja sadrži:
SEQ ID NO: 7 (AM-VH-C)
SEQ ID NO: 8 (AM-VH1)
SEQ ID NO: 9 (AM-VH2-E40)
SEQ ID NO: 10 (AM-VH3-T26-E55)
SEQ ID NO: 11 (AM-VH4-T26-E40-E55)
SEQ ID NO: 12 (AM-VL-C)
SEQ ID NO: 13 (AM-VL1)
SEQ ID NO: 14 (AM-VL2-E40)
13. Anti-Adrenomedulin antitijelo ili fragment anti-ADM antitijela koji se veže na adrenomedulin ili anti-ADM non-Ig skela koja se veže na adrenomedulin za uporabu u terapiji akutne bolesti ili akutnog stanja pacijenta prema bilo kojem od zahtjeva 1 do 12, pri čemu spomenuti pacijent pati od bolesti koja je odabrana od skupine koja sadrži SIRS, sepsu, dijabetes, rak, akutne vaskularne bolesti poput npr. zatajenja srca, šoka poput npr. septičkog šoka i disfunkcije organa poput npr. disfunkcije bubrega.
14. Anti-Adrenomedulin antitijelo ili fragment anti-ADM antitijela koji se veže na adrenomedulin ili anti-ADM non-Ig skela koja se veže na adrenomedulin za uporabu u terapiji akutne bolesti ili akutnog stanja pacijenta prema bilo kojem od zahtjeva 1 do 13, naznačeno time što se spomenuto antitijelo, fragment antitijela ili non-Ig skela ne veže na C-terminalni dio ADM, koji je aa 43-52 od ADM (SEQ ID NO: 25)
PRESKISPQGY -NH2
(SEQ ID NO: 25).
15. Anti-Adrenomedulin antitijelo ili fragment anti-ADM antitijela koji se veže na adrenomedulin ili anti-ADM non-Ig skela koja se veže na adrenomedulin za uporabu u terapiji akutne bolesti ili akutnog stanja pacijenta prema bilo kojem od zahtjeva 1 do 14, za uporabu u kombinaciji s katekolaminom i/ ili fluidima koji se primjenjuju intravenozno.
16. Anti-Adrenomedulin antitijelo ili fragment anti-ADM antitijela koji se veže na adrenomedulin ili anti-ADM non-Ig skela koja se veže na adrenomedulin za uporabu u terapiji akutne bolesti ili akutnog stanja pacijenta prema bilo kojem od zahtjeva 1 do 14, za uporabu u kombinaciji s ADM vezujućim proteinom i/ili daljnjim aktivnim sastojcima.
17. Farmaceutska formulacija koja sadrži anti-Adrenomedulin antitijelo ili fragment anti-ADM antitijela koji se veže na adrenomedulin ili anti-ADM non-Ig skelu koja se veže na adrenomedulin prema bilo kojem od zahtjeva 1 do 16, za uporabu u terapiji akutne bolesti ili akutnog stanja pacijenta prema bilo kojem od zahtjeva 1 - 16.
18. Farmaceutska formulacija prema zahtjevu 17, za uporabu u terapiji akutne bolesti ili akutnog stanja pacijenta prema zahtjevu 17, pri čemu je spomenuta farmaceutska formulacija otopina ili otopina spremna za uporabu.
19. Farmaceutska formulacija prema zahtjevu 17, za uporabu u terapiji akutne bolesti ili akutnog stanja pacijenta prema zahtjevu 17, pri čemu je spomenuta farmaceutska formulacija u brzo-smrznutom stanju.
20. Farmaceutska formulacija koja sadrži anti-Adrenomedulin antitijelo ili fragment anti-ADM antitijela koji se veže na adrenomedulin ili anti-ADM non-Ig skelu koja se veže na adrenomedulin prema bilo kojem od zahtjeva 17 do 19, za uporabu u terapiji akutne bolesti ili akutnog stanja pacijenta prema bilo kojem od zahtjeva 17 do 19, pri čemu je spomenuta farmaceutska formulacija namijenjena za primjenu pacijentu za stabiliziranje sustavne cirkulacije uz uvjet da je spomenutom pacijentu potrebna stabilizacija sustavne cirkulacije.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11189449 | 2011-11-16 | ||
EP12160016 | 2012-03-16 | ||
EP12784632.7A EP2780370B1 (en) | 2011-11-16 | 2012-11-16 | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation |
PCT/EP2012/072932 WO2013072513A1 (en) | 2011-11-16 | 2012-11-16 | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20191771T1 true HRP20191771T1 (hr) | 2019-12-27 |
Family
ID=48429016
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20191771TT HRP20191771T1 (hr) | 2011-11-16 | 2019-09-30 | Anti-adrenomedulin (adm) antitijelo ili fragment anti-adm antitijela ili anti-adm non-ig skela za uporabu u terapiji akutne bolesti ili akutnog stanja pacijenta za stabiliziranje cirkulacije |
Country Status (15)
Country | Link |
---|---|
US (1) | US9402900B2 (hr) |
EP (1) | EP2780370B1 (hr) |
JP (1) | JP6224608B2 (hr) |
AU (1) | AU2012338733B2 (hr) |
CA (1) | CA2856142A1 (hr) |
DK (1) | DK2780370T3 (hr) |
ES (1) | ES2751492T3 (hr) |
HR (1) | HRP20191771T1 (hr) |
HU (1) | HUE045940T2 (hr) |
LT (1) | LT2780370T (hr) |
PL (1) | PL2780370T3 (hr) |
PT (1) | PT2780370T (hr) |
SG (1) | SG11201402358RA (hr) |
WO (1) | WO2013072513A1 (hr) |
ZA (1) | ZA201403549B (hr) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6673847B2 (ja) * | 2013-12-20 | 2020-03-25 | アンギオビオメト ゲゼルシャフト ミット ベシュレンクテル ハフツング | 癌治療に使用するためのアドレノメデュリンバインダー |
US11076813B2 (en) * | 2016-07-22 | 2021-08-03 | Edwards Lifesciences Corporation | Mean arterial pressure (MAP) derived prediction of future hypotension |
EP3339324A1 (en) | 2016-12-22 | 2018-06-27 | sphingotec GmbH | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof |
BR112019011713A2 (pt) * | 2016-12-16 | 2019-10-15 | Adrenomed Ag | anticorpo anti-adrenomedulina (adm) ou fragmento de anticorpo anti-adm ou arcabouço anti-adm não ig para uso na intervenção e terapia da congestão em um paciente com necessidade da mesma |
EP4159230A1 (en) | 2017-09-25 | 2023-04-05 | AdrenoMed AG | Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness |
BR112020005682A2 (pt) | 2017-10-18 | 2020-10-20 | Adrenomed Ag | monitoração de terapia sob tratamento com um aglutinante de antiadrenomedulina (adm) |
EP3871689A1 (en) | 2020-02-26 | 2021-09-01 | sphingotec GmbH | Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c |
CA3169447A1 (en) | 2020-02-27 | 2021-09-02 | Andreas Bergmann | Anti-adrenomedullin (adm) binder for use in therapy of patients in shock |
JP2023515042A (ja) | 2020-02-27 | 2023-04-12 | アドレノメト アクチェンゲゼルシャフト | ショックの治療若しくは予防において使用するための抗アドレノメデュリン(ADM)抗体若しくは抗ADM抗体フラグメント又は抗ADM非Ig足場 |
EP4111204A1 (en) | 2020-02-27 | 2023-01-04 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 for therapy guidance, monitoring and stratification of nt-adm antibodies in patients with shock |
US20210285949A1 (en) | 2020-03-16 | 2021-09-16 | Sphingotec Gmbh | Pro-adrenomedullin or fragment thereof in patients infected with corona virus and treatments with binder against adrenomedullin |
WO2023175035A1 (en) | 2022-03-15 | 2023-09-21 | Adrenomed Ag | Stable aqueous formulation of an anti-adrenomedullin (adm) antibody or anti-adm antibody fragment |
WO2024023368A1 (en) | 2022-07-29 | 2024-02-01 | 4TEEN4 Pharmaceuticals GmbH | Prediction of an increase of dpp3 in a patient with septic shock |
WO2024023369A1 (en) | 2022-07-29 | 2024-02-01 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock |
EP4345109A1 (en) | 2022-09-30 | 2024-04-03 | AdrenoMed AG | Anti-adrenomedullin (adm) binder for use in therapy of pediatric patients with congenital heart disease |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
AU634716B2 (en) | 1988-08-01 | 1993-03-04 | Ciba Corning Diagnostics Corp. | Method for detection of an analyte using acridinium esters and liposomes |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
CA2109602C (en) | 1990-07-10 | 2002-10-01 | Gregory P. Winter | Methods for producing members of specific binding pairs |
AU3328493A (en) | 1991-12-17 | 1993-07-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
JP2774769B2 (ja) * | 1993-04-26 | 1998-07-09 | 賢治 寒川 | アドレノメデュリン |
JPH11512087A (ja) | 1995-08-18 | 1999-10-19 | アメリカ合衆国 | ヒトの病理学及び生理学における、アドレノメジュリン(am)及び遺伝子関連産物(pamp)の機能的役割 |
CA2242308A1 (en) | 1997-12-08 | 1999-06-08 | Smithkline Beecham Laboratoires Pharmaceutiques | Novel compounds |
DE19847690A1 (de) | 1998-10-15 | 2000-04-20 | Brahms Diagnostica Gmbh | Verfahren und Substanzen für die Diagnose und Therapie von Sepsis und sepsisähnlichen systemischen Infektionen |
US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
ES2254220T3 (es) | 1999-09-10 | 2006-06-16 | The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services | Determinacion de proteinas de enlace con la adrnomedulina. |
ATE439588T1 (de) | 2001-05-04 | 2009-08-15 | Biosite Inc | Diagnostische marker für akute herzerkrankungen und verfahren des gebrauchs |
MXPA04001804A (es) | 2001-08-30 | 2005-03-07 | Biorexis Pharmaceutical Corp | Proteinas de fusion de transferrina modificada. |
US6864237B2 (en) | 2002-05-17 | 2005-03-08 | Ping Wang | Treatment of shock using adrenomedullin and adrenomedullin binding protein-1 |
ATE528014T1 (de) | 2002-06-07 | 2011-10-15 | Dyax Corp | Polypeptid mit modifizierten kunitz domains |
DE10316583A1 (de) | 2003-04-10 | 2004-10-28 | B.R.A.H.M.S Aktiengesellschaft | Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung |
EP1620734A1 (en) | 2003-04-25 | 2006-02-01 | Genova Ltd. | Secreted polypeptide species reduced cardiovascular disorders |
US6884781B2 (en) | 2003-05-16 | 2005-04-26 | Ping Wang | Treatment of shock using adrenomedullin binding protein-1 |
US20050164301A1 (en) | 2003-10-24 | 2005-07-28 | Avidia Research Institute | LDL receptor class A and EGF domain monomers and multimers |
US20100028995A1 (en) | 2004-02-23 | 2010-02-04 | Anaphore, Inc. | Tetranectin Trimerizing Polypeptides |
EP1800131A2 (en) | 2004-09-09 | 2007-06-27 | Bayer HealthCare AG | Diagnostics and therapeutics for diseases associated with adrenomedullin receptor (amdr) |
EP1793847A2 (en) | 2004-09-21 | 2007-06-13 | NascaCell IP GmbH | Use of microproteins as tryptase inhibitors |
WO2007062676A1 (en) | 2005-12-01 | 2007-06-07 | B.R.A.H.M.S. Aktiengesellschaft | Methods for the diagnosis and treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists |
KR101686247B1 (ko) * | 2007-10-31 | 2016-12-14 | 메디뮨 엘엘씨 | 단백질 스캐폴드 |
DK2231860T3 (da) | 2007-12-19 | 2011-12-05 | Affibody Ab | Polypeptid afledt protein A og i stand til at binde PDGF |
CA2742241C (en) | 2008-11-03 | 2019-12-10 | Molecular Partners Ag | Binding proteins inhibiting the vegf-a receptor interaction |
CA2772162C (en) | 2009-08-27 | 2018-05-22 | Covagen Ag | Anti-il-17a fynomers and medical uses thereof |
US8748351B2 (en) | 2009-12-14 | 2014-06-10 | Scil Proteins Gmbh | Method for identifying hetero-multimeric modified ubiquitin proteins with binding capability to ligands |
DE102010040035A1 (de) | 2010-03-04 | 2011-09-08 | Robert Bosch Gmbh | Verbesserungen der Rückwärts-Analyse zur Bestimmung von Fehlermaskierungsfaktoren |
ES2729652T3 (es) | 2010-06-08 | 2019-11-05 | Pieris Pharmaceuticals Gmbh | Muteína de lipocalina lacrimal unidas a IL-4R alpha |
FR2964103B1 (fr) | 2010-08-30 | 2018-11-23 | Universite D'aix-Marseille | Anticorps se liant a l'adrenomedulline et aux recepteurs de l'adrenomedulline et leurs utilisations comme medicament |
PL2780717T3 (pl) | 2011-11-16 | 2017-06-30 | Sphingotec Gmbh | Oznaczenia adrenomeduliny i sposoby do oznaczania dojrzałej adrenomeduliny |
-
2012
- 2012-11-16 WO PCT/EP2012/072932 patent/WO2013072513A1/en active Application Filing
- 2012-11-16 EP EP12784632.7A patent/EP2780370B1/en active Active
- 2012-11-16 CA CA2856142A patent/CA2856142A1/en active Pending
- 2012-11-16 DK DK12784632T patent/DK2780370T3/da active
- 2012-11-16 PT PT127846327T patent/PT2780370T/pt unknown
- 2012-11-16 AU AU2012338733A patent/AU2012338733B2/en active Active
- 2012-11-16 ES ES12784632T patent/ES2751492T3/es active Active
- 2012-11-16 JP JP2014541697A patent/JP6224608B2/ja active Active
- 2012-11-16 HU HUE12784632A patent/HUE045940T2/hu unknown
- 2012-11-16 PL PL12784632T patent/PL2780370T3/pl unknown
- 2012-11-16 US US14/358,506 patent/US9402900B2/en active Active
- 2012-11-16 SG SG11201402358RA patent/SG11201402358RA/en unknown
- 2012-11-16 LT LT12784632T patent/LT2780370T/lt unknown
-
2014
- 2014-05-15 ZA ZA2014/03549A patent/ZA201403549B/en unknown
-
2019
- 2019-09-30 HR HRP20191771TT patent/HRP20191771T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
DK2780370T3 (da) | 2019-10-28 |
AU2012338733A1 (en) | 2014-05-29 |
CA2856142A1 (en) | 2013-05-23 |
AU2012338733B2 (en) | 2017-08-24 |
HUE045940T2 (hu) | 2020-01-28 |
PT2780370T (pt) | 2019-10-30 |
SG11201402358RA (en) | 2014-06-27 |
US9402900B2 (en) | 2016-08-02 |
NZ624876A (en) | 2016-08-26 |
US20140322225A1 (en) | 2014-10-30 |
LT2780370T (lt) | 2019-11-25 |
EP2780370A1 (en) | 2014-09-24 |
JP6224608B2 (ja) | 2017-11-01 |
ZA201403549B (en) | 2022-11-30 |
EP2780370B1 (en) | 2019-09-25 |
ES2751492T3 (es) | 2020-03-31 |
PL2780370T3 (pl) | 2020-01-31 |
WO2013072513A1 (en) | 2013-05-23 |
JP2015502349A (ja) | 2015-01-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20191771T1 (hr) | Anti-adrenomedulin (adm) antitijelo ili fragment anti-adm antitijela ili anti-adm non-ig skela za uporabu u terapiji akutne bolesti ili akutnog stanja pacijenta za stabiliziranje cirkulacije | |
RU2014106652A (ru) | Ингибирующие моноклональные антитела против фактора xii/xiia и их применения | |
CN104144948B (zh) | 用于治疗的抗肾上腺髓质素(ADM)抗体或抗ADM抗体片段或抗ADM非Ig骨架 | |
AU2012338731B2 (en) | Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition | |
DK2780371T3 (en) | ANTI-ADDRENOMEDULLIN (ADM) ANTIBODY OR ANTI-ADM ANTISTOFFRAGMENT OR ANTI-ADM NON-IG TEMPLATE FOR REGULATING LIQUID BALANCE OF A PATIENT WITH A CHRONIC OR ACUTE DISEASE | |
JP5068253B2 (ja) | 心臓血管疾患の治療 | |
US9932397B2 (en) | VEGFA/Ang2 Compounds | |
CA2819554A1 (en) | Dosage and administration of bispecific scfv conjugates | |
RU2019122135A (ru) | Антитело против адреномедуллина (adm) или фрагмент анти-adm антитела, или анти-adm не-ig каркас для применения при вмешательстве и терапии гиперемии у пациента | |
JP2023002547A (ja) | 慢性腎疾患の治療のためのデュラグルチド | |
Salam et al. | Pharmacological management of secondary hyperparathyroidism in patients with chronic kidney disease | |
JP2020503013A5 (hr) | ||
Jochberger et al. | Course of vasopressin and copeptin plasma concentrations in a patient with severe septic shock | |
US20120183556A1 (en) | Suppressant for atherosclerosis | |
US20100172909A1 (en) | Cerebral edema suppressant | |
AU2017203484B2 (en) | Use of vanadium compounds for maintaining normaglycemia in a mammal | |
Mishima et al. | Endothelin-1 production via placental (pro) renin receptor in a mouse model of preeclampsia | |
Brettner et al. | The concept of the glycocalyx–Facts that influence perioperative fluid management | |
RU2022112502A (ru) | Соединение, связывающее адреномедуллин (adm), для применения для терапии или профилактики симптомов заболевания | |
Vives | Peri-operative renal protective strategies in cardiac surgery | |
Flessner | Intraperitoneal Chemotherapy 32 | |
Davenport | Chronic Kidney Failure: Renal Replacement Therapy | |
WO2023175035A1 (en) | Stable aqueous formulation of an anti-adrenomedullin (adm) antibody or anti-adm antibody fragment | |
Borghi et al. | Zofenopril is a cost-effective treatment for patients with left ventricular systolic dysfunction following acute myocardial infarction: a pharmacoeconomic analysis of the SMILE-4 study | |
Abe et al. | Bibliography Current World Literature Vol 16 No 2 March 2007 |